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Abstract
Background: We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic
arthritis (JIA).
Methods: In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg +
methotrexate (MTX)(n = 60) or placebo + MTX (n = 62) at weeks 0, 2, and 6. At week 14, patients receiving
placebo + MTX crossed over to infliximab 6 mg/kg + MTX; patients receiving infliximab 3 mg/kg + MTX continued
treatment through week 44. Sera and plasma from eligible patients receiving infliximab 3 mg/kg + MTX (n = 34)
and receiving placebo!infliximab 6 mg/kg +MTX (n = 38) were collected at weeks 0, 2, 14, 16, 28, and 52 and
analyzed for inflammatory markers (IL-6, IL-12p40, ICAM-1, MMP-3, VEGF, TNF-a, and CRP).
Results: At week 2, decreases from baseline in IL-6, ICAM-1, MMP-3, TNF-a, and CRP were greater with infliximab
versus placebo treatment, and with the exception of CRP, these differences were generally maintained through
week 14. The decreases from baseline to week 52 in IL-6, ICAM-1, VEGF, MMP-3, and CRP and increases in IL-12p40
levels were larger in patients receiving placebo!infliximab 6 mg/kg +MTX versus infliximab 3 mg/kg + MTX
treatment. Patients receiving infliximab 3 mg/kg+MTX who achieved an American College of Rheumatology
Pediatric 30 (ACR-Pedi-30) response had significantly larger decreases from baseline in ICAM-1 (p = 0.0105) and
MMP-3 (p = 0.0253) at week 2 and in ICAM-1 (p = 0.0304), MMP-3 (p = 0.0091), and CRP (p = 0.0011) at week 14
versus ACR-Pedi-30 nonresponders.
Conclusion: Infliximab + MTX attenuated several inflammatory markers in patients with JIA; larger decreases in
ICAM-1, MMP-3, and CRP levels were observed in ACR-Pedi-30 responders versus nonresponders.
Trial Registration: NCT00036374
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Background
Juvenile idiopathic arthritis (JIA, formerly referred to as
polyarticular course juvenile rheumatoid arthritis [JRA])
is the most common chronic rheumatic disorder in chil-
dren [1,2]. Tumor necrosis factor-alpha (TNF-a) plays
an important role in the disease process underlying the
chronic inflammation that characterizes JIA. Elevated
serum levels of inflammatory markers TNF-a, interleu-
kin (IL)-6, IL-12 and vascular endothelial growth factor
(VEGF) have been detected in patients with systemic
onset of JIA [3-5]. Increased levels of matrix metallopro-
teinase (MMP)-1 and MMP-3 [6] and more recently IL-
17 [7] have been observed in the synovial fluid of
patients with JIA. Further, elevated levels of intercellular
cell adhesion molecule (ICAM)-1 and E-selectin in
serum have been correlated with active joint count in
JIA patients [8]. Thus, different inflammatory processes
are perpetuated in the JIA disease process and these
may be linked to clinical manifestations.
In the ASPIRE study of adults with early RA, treat-
ment with infliximab plus methotrexate (MTX) resulted
in rapid reductions in levels of MMP-3, ICAM-1, IL-8
and TNF-a [9]. While weekly MTX treatment, at par-
enteral doses up to 15 mg/m2, is an effective and safe
therapy in JIA [10,11], pediatric patients not responding
to MTX may now have other treatment options with
the anti-TNF-a therapies etanercept and adalimumab
[12,13]. Further, in a recent, small study of JIA patients
by Levalampi and colleagues, treatment with infliximab
resulted in reductions in levels of C-reactive protein
(CRP), adhesion molecules (ICAM-1, E -selectin) and
myeloperoxidase [14].
Results from an international, multicenter, rando-
mized, placebo-controlled, double-blind study of the
anti-TNF agent infliximab in the treatment of 122 chil-
dren with persistent polyarticular JRA despite prior
MTX, have been reported. While infliximab treatment
at doses of 3 mg/kg and 6 mg/kg yielded durable effi-
cacy at 1 year, achievement of the primary clinical end-
point (i.e., American College of Rheumatology Pediatric
30 Definition of Improvement [ACR-Pedi-30 response])
at 3 months did not differ significantly between inflixi-
mab 3 mg/kg- and placebo-treated patients [15]. Here
we report the results of a subanalysis of this study that
was performed to determine the effect of infliximab
treatment on select markers of inflammation and assess
correlations between changes in the inflammatory mar-
kers and changes in ACR-Pedi-30 response status.
Methods
Patients and study design
The details of the study design and patient eligibility cri-
teria have been previously described [15]. Briefly, this
substudy was conducted as part of a phase 3, double-
blind, placebo-controlled study of the safety and efficacy
of infliximab in a subset of pediatric patients (age 4-
17 years) of adequate weight (≥35 kg) with JIA (defined
in the study protocol as JRA). Patients were randomized
in a 1:1 ratio to one of two treatment groups. Patients
initially receiving placebo + MTX (n = 62) received pla-
cebo at weeks 0, 2, and 6, and then crossed over to
receive infliximab 6 mg/kg + MTX at weeks 14, 16, 20,
and then every 8 weeks through week 44. Patients in the
infliximab 3 mg/kg + MTX group (n = 60) received
infliximab 3 mg/kg + MTX at weeks 0, 2, 6, 14, 20, and
then every 8 weeks through week 44; these patients also
received a placebo infusion at week 16 to maintain the
study blind. Patients in both groups received concomi-
tant MTX (10 - 15 mg/m2 weekly) throughout the
study. Sera and plasma samples were collected at weeks
0, 2, 14, 16, 28, and 52 in patients with an adequate
body weight (≥35 kg; 34 patients receiving infliximab 3
mg/kg + MTX and 38 patients receiving placebo/inflixi-
mab 6 mg/kg + MTX).
Biomarker assessments
Plasma levels of IL-6 and serum levels of MMP-3,
ICAM-1, IL-12p40, and VEGF were measured using
enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems, Minneapolis, MN). TNF-a levels were mea-
sured using a Bio-plex™ bead-based sandwich enzyme
immunoassay technique (Bio-Rad Laboratories, Her-
cules, CA). These validated analyses were conducted in
a blinded manner at Centocor Ortho Biotech, Inc. Quin-
tiles Laboratories (GA) measured serum CRP concentra-
tions using the Roche Tinaquant assay (Roche
Diagnostics, IN).
Statistical analysis
The median percent changes from baseline in inflamma-
tory marker levels at weeks 2, 14, 16, 28, and 52 were
determined. Statistical comparisons were made between
patients receiving placebo + MTX who crossed over to
receive infliximab 6 mg/kg + MTX and those receiving
infliximab 3 mg/kg + MTX using analysis of variance on
the van der Waerden scores. Univariate Spearman rank
correlations were performed between individual marker
levels at baseline.
Correlation analyses were also performed between
changes from baseline to week 14 for each biomarker
and the number of joints with active arthritis. Baseline
levels and changes from baseline to week 2 and week 14
in levels of inflammatory markers were also compared
between ACR-Pedi-30 responders and nonresponders at
week 14 using analysis of variance on the van der Waer-
den scores. ACR-Pedi-30 responders were defined as
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patients achieving an improvement of at least 30% in
any 3 of the 6 core variables (i.e., physician global
assessment, parent/patient global assessment of overall
well-being, functional ability determined by the Child-
hood Health Assessment Questionnaire [16], number of
joints with active arthritis, number of joints with limited
range of motion, and erythrocyte sedimentation rate)
with no more than one variable worsening by more
than 30% [16]. P-values are provided for exploratory
purposes and are not adjusted for multiplicity.
Results
Baseline characteristics
Baseline patient and disease characteristics were similar
between the two randomized treatment groups. In addi-
tion, no significant differences were observed between
the randomized treatment groups for the median base-
line CRP, IL-6, MMP-3, ICAM-1, IL-12p40, VEGF, or
TNF-a levels (Table 1). Only 14 patients who received
placebo + MTX and 9 patients who received infliximab
3 mg/kg + MTX had TNF-a levels above the lower
limit of quantification of the assay, which restricted sub-
sequent data analyses involving this inflammatory
marker.
Correlations between inflammatory markers at base-
line indicated that the strongest correlations were
between CRP and IL-6 (r = 0.72, p < 0.0001), MMP-3
and CRP (r = 0.53, p < 0.0001), and MMP-3 and IL-6
(r = 0.52, p = 0.0001). Weaker correlations were also
observed between MMP-3 and VEGF, TNF-a and
ICAM-1, TNF-a and IL-12p40, and CRP and ICAM-1
(data not shown). Further, baseline IL-6 and ICAM-1
levels significantly correlated with the number of joints
with active arthritis at baseline (r = 0.37, p = 0.0059; r =
0.32, p = 0.0096; respectively).
Changes in inflammatory marker levels during the
placebo-controlled period assessed at weeks 2 and 14
At week 2, the median percent decreases from baseline
in ICAM-1 (-13.6% vs. -1.7%; p = 0.0353), IL-6 (-61.6%
vs. -15.4%; p = 0.0329), and CRP (-38.1% vs. 0.0%; p =
0.0020) were greater in patients receiving infliximab 3
mg/kg + MTX than in those receiving placebo + MTX.
A 44.9% decrease from baseline to week 2 in MMP-3
was also observed in patients receiving infliximab 3 mg/
kg + MTX, compared with an increase of 0.6% in
patients receiving placebo + MTX (p = 0.0017) (Figures
1A, 1B, 1D, and 1E). In contrast, a larger median per-
cent decrease in IL-12p40 levels was observed in the
placebo + MTX group (-16.6%) than in the infliximab 3
mg/kg + MTX group (-5.0%; p = NS).
Median reductions were numerically higher at week
14 in patients receiving infliximab 3 mg/kg + MTX
compared with those receiving placebo + MTX for
ICAM-1 (-14.4 vs. -0.4; p = NS), IL-6 (-51.6 vs. -16.2;
p = NS), VEGF(-13.3 vs. -6.7; p = NS), and MMP-3
(-42.4 vs. 0.7; p = 0.0120) levels (Figures 1A-D. The
decreases in CRP and IL-12p40 levels observed at week
14 were greater in patients receiving placebo + MTX
(-31.8 and -19.4, respectively) than in those receiving
infliximab 3 mg/kg + MTX (-24.7 and -2.0, respectively),
but these changes were not significant (p = 0.9111 and
0.0622, respectively; Figures 1E, 1F).
Change in inflammatory marker levels during the
crossover period assessed at weeks 16, 28, and 52
By week 20, at which point all patients were receiving
either 3 or 6 mg/kg infliximab + MTX, reduced levels of
inflammatory markers were observed in both treatment
groups for ICAM-1, IL-6, VEGF, MMP-3 and CRP (Fig-
ures 1A-E. Levels of IL-12p40 had also declined in the
infliximab 3 mg/kg + MTX group, but showed an
increase (3.5%) at week 16 in patients receiving placebo
who crossed over to receive infliximab 6 mg/kg + MTX
(Figure 1F).
Variable changes from baseline were observed across the
inflammatory markers in patients receiving infliximab 3
mg/kg + MTX or infliximab 6 mg/kg + MTX at weeks 28
and 52. While inflammatory marker levels tended to
rebound somewhat over time in the infliximab 3 mg/kg
group, ICAM, IL-6, VEGF, MMP-3 and CRP levels at
week 52 were generally below levels observed at baseline
(Figures 1A-E). Conversely, IL-12p40 levels were slightly
increased from baseline to week 52 (Figure 1F). The
decreases from baseline to week 52 in IL-6, ICAM-1,
MMP-3, and CRP and increases in IL-12p40 levels were
larger in patients receiving placebo + MTX who crossed
over to receive infliximab 6 mg/kg + MTX as compared
with patients receiving infliximab 3 mg/kg + MTX. Only
the differences in IL-6 (-77.8% vs. -37.7%; p = 0.0098,
respectively) and MMP-3 (-70.2% vs. -23.8%; p = 0.0258,
respectively) were statistically significant (data not shown).
Associations between inflammatory marker levels and
clinical response as assessed by ACR-Pedi-30 response
and the number of joints with active arthritis
At week 2, among patients receiving placebo + MTX,
significantly larger median percent decreases in IL-6
(-49.6% vs. 6.8%; p = 0.0344) were observed in patients
who were ACR-Pedi-30 responders as compared with
ACR-Pedi-30 nonresponders. These results indicated a
significant association between changes in IL-6 levels
and ACR-Pedi-30 response in patients treated with pla-
cebo + MTX (Table 2). Significantly larger median per-
cent decreases in ICAM-1 (p = 0.0105) and MMP-3
(p = 0.0253) were also observed among ACR-Pedi-30
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responders when compared with nonresponders in the
infliximab 3 mg/kg + MTX group (Table 2).
At week 14, in patients receiving infliximab 3 mg/kg +
MTX, ACR-Pedi-30 responders had larger median per-
cent reductions than ACR-Pedi-30 nonresponders in
ICAM-1 (-21.7% vs. 4.8%; p = 0.0304), MMP-3 (-55.5%
vs. 8.2%; p = 0.0091), and CRP (-55.0% vs. 0.0%; p =
0.0011; Table 2).
Also, at week 14, decreases in IL-6, VEGF, and CRP
levels correlated with the number of joints with active
arthritis in patients treated with infliximab 3 mg/kg +
MTX (r = 0.52, p = 0.005; r = 0.44, p = 0.011; r = 0.29,
p = 0.027; respectively). In the placebo + MTX group,
changes in ICAM-1 and CRP levels were significantly
correlated with the number of joints with active arthritis
at week 14 (r = 0.64, p < 0.0001; r = 0.38, p = 0.004;
respectively) (data not shown).
Discussion
JIA involves an inflammatory process that if unabated
will eventually lead to bone and cartilage damage.
Thus we examined markers associated with inflamma-
tion (IL-6, ICAM-1, MMP-3, VEGF, IL-12p40, TNF-a,
and CRP) that may be modulated by infliximab +
MTX therapy. Although the primary clinical endpoint
for this study was not achieved, results of the current
analysis indicate that significant reductions from base-
line in IL-6, ICAM-1, MMP-3, and CRP levels were
observed as early as week 2 and sustained through
week 14 of treatment with infliximab 3 mg/kg + MTX,
relative to treatment with placebo + MTX. Similar
findings were reported by Levalampi and colleagues,
who reported reductions in CRP, IL-6 and ICAM-1
levels by week 6 in JIA patients treated with infliximab
[14]. Taken together, these findings suggest that early
decreases in these biomarkers are an indication of dis-
ease modulation.
Further, in the current study, larger decreases in IL-6,
ICAM-1, MMP-3 and CRP and increases in IL-12p40
levels were observed in patients receiving placebo +
MTX who crossed over to receive infliximab 6 mg/kg +
MTX relative to treatment with infliximab 3 mg/kg +
MTX. Increased IL-12 and interferon gamma (IFNg)
mRNA expression has previously been detected in syno-
vial tissue from JIA patients, which suggests that IL-12
may have an important role in this disease [17]. The
increase in IL-12 levels in infliximab-treated patients
may reflect a shift in the disease processes resulting
from substantial reduction of peripheral TNF-a levels.
In patients treated with infliximab 3 mg/kg + MTX,
those who achieved an ACR-Pedi-30 response showed
significant reductions in ICAM-1, MMP-3, and CRP
levels compared with those who did not achieve an
Table 1 Disease characteristics and biomarker levels at
baseline*
Placebo!Infliximab
6 mg/kg + MTX
Infliximab 3
mg/kg +
MTX
Patients included in substudy 38 34
Age at study entry, yrs 12.7 (3.3) 13.4 (2.8)
Disease characteristics
Disease duration, yrs 4.03 (3.92) 4.89 (4.4)
Number of joints with
active arthritis
n 38 34
Range (5.0, 47.9) (5.0, 44.0)
Median 16.0 13.5
Number of joints with
limited range of motion
n 38 34
Range (4.0, 48.4) (2.0, 42.0)
Median 15.0 12.5
Inflammatory markers
C-reactive protein, mg/dL
n 38 34
Range (0.4, 7.4) (0.4, 10.5)
Median 0.8 0.9
TNF-a (pg/mL)
n 14 9
Range (1.6, 30.9) (1.6, 24.4)
Median 1.6 1.6
IL-6 (pg/mL)
n 28 27
Range (0.4, 93.7) (0.1, 79.3)
Median 8.2 3.4
MMP-3 (ng/mL)
n 32 32
Range (2.7, 390.2) (0.8, 570.0)
Median 39.3 40.3
ICAM-1 (ng/mL)
n 34 32
Range (200.2, 767.9) (18.6, 1059.2)
Median 394.0 375.4
VEGF (ng/mL)
n 33 32
Range (83.3, 1535.2) (29.8, 1447.0)
Median 440.2 317.8
IL-12p40 (pg/mL)
n 34 30
Range (15.5, 357.9) (15.6, 357.9)
Median 84.3 95.6
Values are presented as mean (SD) unless otherwise noted.
* Only patients with biomarker values above the lower limit of quantification
of specific assays were included in analyses, which accounts for differences
between numbers of patients sampled for each inflammatory marker.
MTX, methotrexate; IL-6, interleukin-6; MMP-3, matrix metalloproteinase-3;
ICAM-1, intracellular cell adhesion molecule-1; VEGF, vascular endothelial
growth factor; IL-12p40, interleukin 12; TNF-a, tumor necrosis factor-a.
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ACR-Pedi-30 response. Further, decreases in IL-6,
VEGF, and CRP levels were correlated with the number
of joints with active arthritis. These results suggest that
ICAM-1, MMP-3, IL-6, VEGF, and CRP might be useful
surrogate markers to monitor improvement in the signs
and symptoms of JIA and joints with active arthritis
after initiation of treatment with infliximab + MTX
therapy.
This biomarker substudy has several limitations. First,
the substudy was designed as an exploratory assessment
of changes in inflammatory biomarker levels after inflixi-
mab 3 mg/kg + MTX therapy versus treatment with pla-
cebo + MTX therapy in patients with JIA. Second, the
patients evaluated in both treatment groups were limited
to those who were of adequate body weight (≥35 kg)
and analyses were based only on patients with levels of
Figure 1 Change in median levels of serum inflammatory markers over time in patients who received infliximab 3 mg/kg + MTX or
placebo + MTX through week 14 with a crossover to infliximab 6 mg/kg + MTX for ICAM-1 (A), IL-6 (B), VEGF (C), MMP-3 (D), CRP (E),
and IL-12p40 (F). MTX, methotrexate; ICAM-1, intracellular cell adhesion molecule-1; IL-6, interleukin-6; VEGF, vascular endothelial growth factor;
MMP-3, matrix metalloproteinase-3; CRP, C-reactive protein; IL-12p40, interleukin 12.
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inflammatory markers above the lower limit of quantifi-
cation for each assay. Further, median TNF-a levels
were not substantially elevated, which indicates that sys-
temic levels of this biomarker are low in this evaluated
patient population. An additional limitation of this sub-
study was the inability to measure free TNF-a after
infliximab treatment since the available commercial
TNF-a assays were not designed to distinguish “free”
from “infliximab-bound” TNF-a. These study limitations
may have limited our ability to detect potentially signifi-
cant associations between biomarker changes and
improvement in clinical signs and symptoms in either
the placebo + MTX crossover or infliximab 3 mg/kg +
MTX groups, or to determine if these trends would be
the same in patients who weighed less than 35 kg.
Conclusions
Findings of this biomarker substudy suggest that changes
in ICAM-1, MMP-3, IL-6, VEGF and CRP levels may be
useful markers to evaluate response to infliximab therapy
in patients with JIA and thus may enable early identifica-
tion of patients who could benefit from this treatment.
Larger studies will be required to confirm the current
preliminary findings and establish the relevance of these
markers in predicting changes in signs and symptoms, as
well as structural damage, of JIA.
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